NCT04084366: Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

NCT04084366
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known untreated unstable central nervous system metastases
https://ClinicalTrials.gov/show/NCT04084366

Comments are closed.

Up ↑